Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

23.91 -0.24 (-0.99%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
Down 65%, Is Viking Therapeutics Stock a Buy on the Dip?
Via The Motley Fool
Viking Therapeutics Stock Down Over 20% In 2025: Retail Traders Predict Where It Could End The Year
In 2024, Viking reported positive results from four different clinical trials, including a Phase 2 study for subcutaneous VK2735 and a Phase 1 trial of an oral tablet form of VK2735 to treat obesity. 
Via Stocktwits
We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug Wars
Lilly’s fiercest competitor in the obesity market is Novo Nordisk, which offers Ozempic and Wegovy. However, rising threats from other players such as Hims & Hers, Amgen, and Viking Therapeutics also... 
Via Stocktwits
Market Movers: $ASTS Surges Again, $PBI Gears Up For Earnings!
Pre-Market Briefing: Feb 6 – Top trade setups using our 4-pillar strategy! $ASTS leads the way, $PBI gears up for earnings, and $PTON & $APPS ride post-earnings momentum. 
Via Talk Markets
Topics Stocks / Equities
Has the Bubble Burst for Viking Therapeutics Stock?
Via The Motley Fool
Earnings Scheduled For February 5, 2025
Via Benzinga
(VKTX) - Analyzing Viking Therapeutics's Short Interest
Via Benzinga
This Biotech Stock Soared 116% in 2024, but Is It a Buy in 2025?
Via The Motley Fool
Here's How Much $1000 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today
Via Benzinga
Viking Therapeutics Plummeted 10% On Its Earnings Report. Here's Why.
Viking Therapeutics stock plunged late Wednesday on an earnings report that included mostly incremental updates. 
Via Investor's Business Daily
Viking Therapeutics Shares Drop After Q4 EPS Miss Estimates
Viking Therapeutics announces its fourth-quarter financial results after Wednesday's closing bell. Here's a look at the details from the report. 
Via Benzinga
This Weight Loss Stock Could Soar Over 220%, According to Wall Street. Time to Buy?
Wall Street has high hopes for development-stage pharmaceutical company Viking Therapeutics. 
Via The Motley Fool
Jim Cramer: This Industrial Stock Is 'Absolutely Terrific', First Solar Is 'Very Inexpensive'
First Solar will report financial results for the fourth quarter and full year ended Dec. 31, 2024, after the closing bell on Tuesday, Feb. 25, 2025. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Here's How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 5 Years
Via Benzinga
Novo Nordisk Jumps On Experimental Weight-Loss Drug Trial Results
The Danish drug giant reported a 22% weight loss over 36 weeks. 
Via Investor's Business Daily
Top 3 Health Care Stocks That Could Blast Off This Quarter
Via Benzinga
Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today
Via The Motley Fool
We Asked Retail How Viking Therapeutics Can Restore Investor Confidence: Majority Say Pursue Buyout Talks
Oppenheimer earlier this month listed Viking as one of five biotech companies that could be prime candidates for an "aspirational" takeover. 
Via Stocktwits
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday
Via The Motley Fool
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
3 Mid-Cap Stocks That Could Take Off in 2025
Via The Motley Fool
Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst
JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights. 
Via Benzinga
1 Under-the-Radar Stock to Buy Before It Soars by 156%, According to Select Wall Street Analysts
This is a high-risk, high-reward stock. 
Via The Motley Fool
Why Viking Therapeutics Stock Plummeted by 24% in December
Via The Motley Fool
Should You Buy the Dip on This High-Flying Stock?
Via The Motley Fool
StoryTrading's Secrets To January Gains - Don’t Miss These Picks
As we usher in the new year, market dynamics continue to be shaped by a blend of tax-deferral selling, the January effect, and macro uncertainties. 
Via Talk Markets
Topics Stocks / Equities
3 Stocks That Could Be Monster Winners in 2025
Via The Motley Fool
Down 18% in 1 Day, Is Viking Therapeutics Stock in Trouble Due to Merck?
Via The Motley Fool
My Top 10 Stocks to Buy for 2025
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.